After-cataract or posterior capsule opacification (PCO) remains the most common long-term complication of modern cataract-surgery. Recent investigations showed a significant alteration of Elschnig pearls and signs of reorganisation during a period of weeks. Little is known about the pharmaceutical influence on these processes.
Conditions
Interventions
Trade Name: Ultracortenol
Product Name: Ultracortenol
Pharmaceutical Form: Eye drops*
Trade Name: Voltaren Ophta
Product Name: Voltaren Ophta
Pharmaceutical Form: Eye drops*
Sponsors
Univ.-Prof. Dr. Oliver Findl Med. Univ. Wien
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Pseudophakic eye with dense regeneratory PCO - Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - tear film problems - corneal pathology - dense vitreous opacities - pupil diameter of less than 5 mm after dilatation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Aim of this study is to observe and document the effect of steroidal and nonsteroidal anti-inflammatory treatment on the morphological changes of PCO.;Secondary Objective: ;Primary end point(s): Main outcome variable: Change in number and size of Elschnig pearls (Posterior capsule opacification) (subjective assessment) Additional outcome variables Subjective description of morphological changes between images | — |
Countries
Austria
Outcome results
None listed